RSNA 2023: Leading through Change in AI for diagnosis, treatment, care, interoperability
The Technical Exhibits within the 109th Scientific Assembly and Annual Meeting Radiological Society of North America (RSNA), IL, USA have ended after four immersive days, November 26 to 29, of buzzing and breaking advancements across many healthcare subspecialties.
Proud to be one of the 113 first-time RSNA exhibitors, VinBrain marks the first time a Vietnamese AI HealthTech start-up has participated in this biggest global Healthcare conference.
“VinBrain’s evolving product portfolio of AI solutions is being rapidly adopted by physicians,” said Prof. Dr. Gregory Moore, Associate Fellow Center for Artificial Intelligence and Medical Imaging (AIMI) at Stanford University School of Medicine, former Vice President of Microsoft Health global and Google Cloud Healthcare.
VinBrain’s presence at RSNA goes beyond mere company introduction; it’s about learning from and aligning with fellow attendees in our shared mission to deliver high-quality diagnostic radiology care more efficiently and safely.
VinBrain gained attention with new game-changers for radiologic AI and streamlining hospital operations.
In the exclusive launch at 10:30 am (CT), November 27, the company has debuted two new game-changer solutions, encompassing DrAid™ Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid™ Oncology Diagnosis and Treatment (D&T).
Expediting interoperability and streamlining, DrAid™ Enterprise Data Solution (EDS) is hoped to lead the healthcare transformation towards precision care. EDS brings a knowledge engine based on big data whose core is “to transfigure massive medical raw data into actionable knowledge and insights”, said Steven Truong, Founder & CEO VinBrain.
EDS is capable of auto-generating reports multilingually in more than 25 languages. It helps doctors summarise examination history and highlight differences between reports and medical images. Besides, it provides personalised Electrical Medical Records Analytics and smart EMR search. For hospital operators, EDS delivers real-time insights through intuitive multi-dashboards and AI predictive analysis, empowering data-driven decisions for resource allocation. The excitement extends to DrAid™ Copilot – a medical AI-powered virtual assistant that helps healthcare professionals look up, extract data, and enhance productivity through natural language interaction. All the EDS modules are organised under the secure and centralised Data Lake and Data Management infrastructure, converting data to structured formats, and massive silos into a repository for world-class security and lasting and centralised storage for operative and R&D purposes.
Oncology D&T, on the other hand, proves a broader adoption of AI to more accurate diagnosis and improved treatment decisions for the most complex diseases of mankind’s history. VinBrain is enlisted among the few pioneers in the world to develop a screening and treatment-aiding platform to empower the fight against liver and rectal cancer, two of the top 10 deadliest cancers in the world.
The innovative AI-powered solutions, CT Liver Cancer D&T and MRI Rectal Cancer D&T reveal the intricacies of cancer classification, localisation, and measurement, enabling early detection and offering hope for saving more lives. Notably, CT Liver Cancer D&T can detect hepatocellular carcinoma (HCC), the most common liver malignancy. This solution utilises a novel method based on wavelet radiomics features from multiphase CT images for HCC screening. The study of this method was recently published in Nature Scientific Reports just ahead of RSNA 2023, coinciding with CT Liver Cancer D&T advancing to the final round of the ASEAN Digital Innovation 2023 Awards.
The Oncology D&T utilises all the SOTA, including the nnUnet, ConvNeXt, and attention techniques. It is trained on and validated in high-quality and large datasets, confirmed by experienced radiologists. By providing comprehensive information, it aids oncologists in weighing treatment and surgery options such as surgical resection and transarterial chemoembolization (TACE), and total mesorectal excision (TME). Oncology D&T aim is to extend the life expectancy for a healthier life for patients and work as a second reader, while is beneficial to improve the workflow triage.
Guided by a quality-first approach throughout our 4-year journey, VinBrain prioritises our strategic collaboration with esteemed institutions like Stanford University. As a guest speaker, Dr. Michael C. Muelly, Clinical Assistant Professor of Radiology at Stanford University, VinBrain’s Medical Partner shared: “I enjoyed spending time on the product launch. It’s great to see what VinBrain is working up, very excited to see what is coming. The opportunities for AI to make big impacts around the world and medicine are huge. Viet Nam could be the place where it happens, starts, and spreads from there.”
DrAid™’ can be easily integrated and deployed into many systems (PACS, HIS, RIS, EMR…), with the option of cloud or on-premises availability through the DrAid™ Appliance. VinBrain’s team collaborates with NVIDIA biweekly to take advantage of NVIDIA’s 48 GPUs, besides MONAI, and Tensor RT. DrAid™ adheres to HIPAA and NIST standards by employing Azure, ensuring robust privacy and security.
At RSNA 2023, VinBrain also showcased its commitment to providing accessible healthcare in underserved regions with high tuberculosis burden through DrAid™ for Tuberculosis Screening (CXR Screening). This cost-effective solution enables large-scale screenings for an estimated 10.6 million TB-suspected individuals, garnering substantial praise from other exhibitors.
Continue to learn and thrive!
As Artificial Intelligence continues to make strides in radiology, such participation is a valued experience for VinBrain in every aspect including research and development, innovation and commercialisation capacity. With in-person fruitful discussions with nearly 500 visitors for four days, as well as witnessing 670 industry leaders at the Exhibits, VinBrain and its flagship product – DrAid™ has gained a lot of knowledge to reinforce the global expansion strategy and are poised to make a significant impact in the SEA, US, India, UK/EU, and Middle East markets between 2024 – 2027.
